Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
Jayastu Senapati, Elias Jabbour, Hagop M. Kantarjian, et al.
Leukemia (2022) Vol. 37, Iss. 1, pp. 5-17
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
Elias Jabbour, Hagop M. Kantarjian
American Journal of Hematology (2024) Vol. 99, Iss. 11, pp. 2191-2212
Open Access | Times Cited: 21
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
Nicholas C.P. Cross, Thomas Ernst, Susan Branford, et al.
Leukemia (2023) Vol. 37, Iss. 11, pp. 2150-2167
Open Access | Times Cited: 41
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1
Nicholas J. Short, Elias Jabbour, Walid Macaron, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 8, pp. 1196-1203
Closed Access | Times Cited: 40
Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy
Jayastu Senapati, Hagop M. Kantarjian, Diane Habib, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-12
Closed Access | Times Cited: 1
Chronic Myeloid Leukemia
Elias Jabbour, Hagop M. Kantarjian
JAMA (2025)
Closed Access | Times Cited: 1
Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations
Stephanie Sembill, Maria Ampatzidou, Sonali Chaudhury, et al.
Leukemia (2023) Vol. 37, Iss. 3, pp. 505-517
Open Access | Times Cited: 19
Chronic myeloid leukaemia: Biology and therapy
Yun Wang, Zhi-Jian Liang, Robert Peter Gale, et al.
Blood Reviews (2024) Vol. 65, pp. 101196-101196
Closed Access | Times Cited: 8
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry
Annamaria Brioli, Elza Lomaia, Christian Fabisch, et al.
Leukemia (2024) Vol. 38, Iss. 5, pp. 1072-1080
Open Access | Times Cited: 8
Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia
Jingnan Sun, Ruiping Hu, Mengyuan Han, et al.
International Journal of Biological Sciences (2023) Vol. 20, Iss. 1, pp. 175-181
Open Access | Times Cited: 15
SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia
Jayastu Senapati, Hagop M. Kantarjian, Fadi G. Haddad, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 6, pp. 333-339
Closed Access | Times Cited: 5
Advancing Early Leukemia Diagnostics: A Comprehensive Study Incorporating Image Processing and Transfer Learning
Rezaul Haque, Abdullah Al Sakib, Md. Forhad Hossain, et al.
BioMedInformatics (2024) Vol. 4, Iss. 2, pp. 966-991
Open Access | Times Cited: 5
Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress
Hagop M. Kantarjian, Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 9, pp. 1350-1353
Closed Access | Times Cited: 11
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape
Fang Chen, Dandan Zhao, Yongfang Xu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
Jiang Guoyun, Qin Yuefeng, Huang Zhenglan, et al.
Experimental Hematology and Oncology (2025) Vol. 14, Iss. 1
Open Access
Repositioning of FDA-approved anti-cancer drugs for fatal blast crisis CML by integrated high-throughput genomic and artificial intelligence-based drug discovery analyses of pan-leukemic genetic abnormalities: Implications in post-COVID-19 era
Zafar Iqbal, Nawaf Alanazi, Sarah AlMukhaylid, et al.
Research Square (Research Square) (2025)
Closed Access
5-FU@HFn combined with decitabine induces pyroptosis and enhances antitumor immunotherapy for chronic myeloid leukemia
Zuowei Yuan, Guoyun Jiang, Ying Yuan, et al.
Journal of Nanobiotechnology (2025) Vol. 23, Iss. 1
Open Access
Undocumented Safety Signals of Imatinib: Pharmacovigilance Insights from the FDA Adverse Event Reporting System (FAERS) and Implications for Clinical Practice
Tianqin Xia, Bo Shu, Yuan Peng, et al.
(2025)
Closed Access
Meisoindigo Acts as a Molecular Glue to Target PKMYT1 for Degradation in Chronic Myeloid Leukemia Therapy
Z Y Zhang, Shuying Li, Fang‐Fei Li, et al.
Advanced Science (2025)
Open Access
Structure and Dynamics of the ABL1 Tyrosine Kinase and Its Important Role in Chronic Myeloid Leukemia
Ayca Irgit, Reyhan Kamıs, Belgin Sever, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 5
Open Access
Research on the functions and potential mechanisms of STAT3 in chronic myelogenous leukemia
Xingmin Feng, Ya‐Zhen Qin, Yi Feng, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study
Ziyu Wen, Zhi Liu, Xu Ye, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial
Nicholas J. Short, Daniel Nguyen, Elias Jabbour, et al.
The Lancet Haematology (2024) Vol. 11, Iss. 11, pp. e839-e849
Closed Access | Times Cited: 3
Molecular Evaluation of the Impact of Polymorphic Variants in Apoptotic (Bcl-2/Bax) and Proinflammatory Cytokine (TNF-α/IL-8) Genes on the Susceptibility and Progression of Myeloproliferative Neoplasms: A Case-Control Biomarker Study
Mamdoh S. Moawadh, Rashid Mir, Faris J. Tayeb, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 5, pp. 3933-3952
Open Access | Times Cited: 7
Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model
Jusuf Imeri, Paul Marcoux, Matthias Huyghe, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 2
Dynamic Single-Cell RNA-Seq reveals mechanism of Selinexor-Resistance in Chronic myeloid leukemia
Yunqi Cui, Yating Li, Jiamei Ji, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112212-112212
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top